<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4)*
AMYLIN PHARMACEUTICALS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 par value
------------------------------
(Title of Class of Securities)
032346108
--------------
(CUSIP Number)
Eric B. Jung, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(732) 524-1249
--------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
February 9, 2000
------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
<TABLE>
SCHEDULE 13D
CUSIP NO. 032346108 PAGE 2 OF 6 PAGES
--------- ----- ----
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson 22-1024240
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / /
(B) / /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF ------------------------------------------------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY
EACH 3,963,357
REPORTING ------------------------------------------------------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH
-0-
------------------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,963,357
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,963,357
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.15 %
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
<TABLE>
SCHEDULE 13D
CUSIP NO. 032346108 PAGE 3 OF 6 PAGES
--------- ----- ----
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson Development Corporation 22-2007317
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / /
(B) / /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF ------------------------------------------------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY
EACH 3,963,357
REPORTING ------------------------------------------------------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH
-0-
------------------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,963,357
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,963,357
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.15 %
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
Page 4 of 6 pages
This Amended Schedule 13D is being filed to reflect changes in the
ownership by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson &
Johnson Development Corporation, a New Jersey corporation ("JJDC" and together
with J&J, "Reporting Persons"), of shares of Common Stock, $.001 par value (the
"Common Stock") of Amylin Pharmaceuticals, Inc. (the "Company"). In addition,
this Amended Schedule 13D corrects certain information contained in the Amended
Schedule 13D filed by the Reporting Persons on February 11, 2000 with respect to
the ownership of Common Stock. Items 3, 4 and 5 of the Statement on
Schedule 13D filed pursuant to Rule 13d-1 of the Rules and Regulations under the
Securities Exchange Act of 1934, as amended, by J&J and JJDC, relating to the
shares of Common Stock, are hereby amended as follows:
Item 3. Source and Amount of Funds or Other Consideration:
On September 30, 1997, the Company issued to J&J Warrants to purchase
1,530,950 shares of Common Stock, at an exercise price of $12.00 per
share, with an expiration date of September 29, 2007. The Warrants
were issued pursuant to the terms of the Loan and Security Agreement
between the Company and J&J and as a result of the Promissory Note of
the Company in favor of J&J dated September 30, 1997 in the principal
amount of $30,619,000.
Item 4. Purpose of Transaction:
The Collaboration Agreement was terminated by LifeScan, Inc., a
wholly-owned subsidiary of J&J, on February 23, 1998 effective August
23, 1998.
Not otherwise applicable in that the transaction involved sales and not
acquisitions of securities. The Reporting Persons reserve the right to
repurchase additional shares of Common Stock or to dispose of shares
of the Common Stock in the open market, in privately negotiated
transactions or in any other lawful manner in the future. Except as
described above, the Reporting Persons presently have no plans or
proposals which relate to or would result in any action enumerated in
subparagraphs (a) through (j) of the instructions for Item 4 of
Schedule 13D.
<PAGE> 5
Page 5 of 6 pages
Item 5. Interest in Securities of the Issuer:
(a) - (b)
As of February 15, 2000, J&J and JJDC each had beneficial ownership of
an aggregate of 3,963,357 shares of Common Stock. Based upon the
shares of Common Stock outstanding as of February 4, 2000, as
reported in the Company's Report on Form S-3/A dated February 4, 2000,
3,963,357 shares constitute approximately 7.15% of the outstanding
shares of Common Stock.
(c) The following sales of Common Stock have been made by the
Reporting Persons in the past sixty (60) days(*):
<TABLE>
<CAPTION>
Amount of Where and How
Date of Securities Price Acquired (A) Transaction
Transaction Involved per Share or Disposed (D) was Effected
------------ -------- --------- --------------- ----------------------------
<S> <C> <C> <C> <C>
02/08/00 58,000 $14.3114 (D) Over-the-Counter transaction
through a broker
02/09/00 35,000 $14.5357 (D) Over-the-Counter transaction
through a broker
02/10/00 190,000 $13.8355 (D) Over-the-Counter transaction
through a broker
02/11/00 150,000 $13.5208 (D) Over-the-Counter transaction
through a broker
02/14/00 110,000 $11.9517 (D) Over-the-Counter transaction
through a broker
</TABLE>
To the best knowledge of J&J and JJDC, no director or executive officer
of J&J or JJDC beneficially owns any shares of Common Stock or other
securities of the Company. Neither J&J nor JJDC is aware of any
transaction in such securities during the past sixty (60) days by any
of its executive officers or directors.
(e) This Amended Schedule 13D corrects certain information contained
in the Amended Schedule 13D filed by the Reporting Persons on February
11, 2000 with respect to the beneficial ownership of Common Stock.
Consequently, neither this Amendment nor American No. 3 constitutes a
final filing.
-------------
(*) As of the close of business on February 15, 2000.
<PAGE> 6
Page 6 of 6 pages
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
JOHNSON & JOHNSON
By: /s/ Michael Ullmann
-------------------
Michael Ullmann
Secretary
Date: February 15, 2000
JOHNSON & JOHNSON
DEVELOPMENT CORPORATION
By: /s/ E. Jung
-------------------
E. Jung
Secretary
Date: February 15, 2000
